- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02596841
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias (Dm&Vc)
Study Overview
Status
Detailed Description
Rationale: Lung diffusing capacity for carbon monoxide (DLCO) is decreased in both usual interstitial pneumonia-idiopathic pulmonary fibrosis (UIP-IPF) and nonspecific interstitial pneumonia (NSIP), but is weakly related to computed tomography (CT)-determined fibrotic changes.
Objectives: To determine whether measurement of lung diffusing capacity for nitric oxide (DLNO) better reflects fibrotic changes than DLCO.
Methods: DLNO and DLCO were measured simultaneously in 30 patients with UIP-IPF and 30 with NSIP. The amount of pulmonary fibrosis was estimated by volumetric analysis of visually bounded areas showing reticular opacities and honeycombing. Alveolar membrane conductance (DMCO) and pulmonary capillary volume (Vc) were calculated.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Chest computed tomography (CT) scan diagnosis of either usual interstitial pneumonia-idiopathic pulmonary fibrosis (UIP-IPF) or idiopathic nonspecific interstitial pneumonia (NSIP)
Exclusion Criteria:
- Symptoms/signs or specific serum markers of an underlying autoimmune process
- Previous environmental/occupational exposure to fibrogenic dusts
- Use of fibrogenic medications
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of lung diffusing capacity for nitric oxide (DLNO) in a group of 60 patients with fibrosing idiopathic interstitial pneumonias (IIPs)
Time Frame: Within 1 month following idiopathic interstitial pneumonias diagnosis
|
Because DLNO is more sensitive to alveolar membrane diffusive conductance (DMCO) than standard lung diffusing capacity for carbon monoxide, DLNO changes may better reflect the extent of fibrotic process in IIPs
|
Within 1 month following idiopathic interstitial pneumonias diagnosis
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Guenard H, Varene N, Vaida P. Determination of lung capillary blood volume and membrane diffusing capacity in man by the measurements of NO and CO transfer. Respir Physiol. 1987 Oct;70(1):113-20. doi: 10.1016/s0034-5687(87)80036-1.
- Borland CD, Higenbottam TW. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J. 1989 Jan;2(1):56-63.
- Wemeau-Stervinou L, Perez T, Murphy C, Polge AS, Wallaert B. Lung capillary blood volume and membrane diffusion in idiopathic interstitial pneumonia. Respir Med. 2012 Apr;106(4):564-70. doi: 10.1016/j.rmed.2011.12.011. Epub 2012 Jan 4.
- Barisione G, Brusasco C, Garlaschi A, Baroffio M, Brusasco V. Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. J Appl Physiol (1985). 2016 May 1;120(9):1029-38. doi: 10.1152/japplphysiol.00964.2015. Epub 2016 Feb 18.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRCCS 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Usual Interstitial Pneumonia
-
Turkish Thoracic SocietyTerminatedIdiopathic Pulmonary Fibrosis | Usual Interstitial PneumoniaTurkey
-
Maastricht UniversityUniversité Libre de BruxellesCompletedIdiopathic Pulmonary Fibrosis | Interstitial Lung Disease | Usual Interstitial PneumoniaNetherlands
-
McGill University Health Centre/Research Institute...McGill UniversityRecruitingRheumatic Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Interstitial Lung Disease | Usual Interstitial Pneumonia | Nonspecific Interstitial Pneumonia | Rheumatic Arthritis | Systemic Autoimmune Disease | Autoimmune MyositisCanada
-
Lawson Health Research InstituteRecruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Nonspecific Interstitial PneumoniaCanada
-
Università Politecnica delle MarcheUnknown
-
National Jewish HealthUniversity of Colorado, Denver; Vanderbilt University; Landspitali University...RecruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Familial Pulmonary Fibrosis | Familial Interstitial PneumoniaUnited States, Iceland
-
North East Japan Study GroupBoehringer IngelheimActive, not recruiting
-
University of HoustonTexas Women's UniversityRecruitingTreatment as Usual | MISC InterventionUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedIdiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditionsUnited States, Germany
-
DePaul UniversityNational Institute on Drug Abuse (NIDA)CompletedUsual Aftercare | Oxford House | Therapeutic CommunityUnited States